Currently patients with glioblastoma have a median survival of approximately 14.6 months and 5-year survival rates below 5%.

The Archbishop of York, Stephen Cottrell—an archbishop who should have resigned over failed safeguarding issues—now feels it ...

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) use was significantly associated with a reduced odds of five-year mortality, but this protective effect was found to be statistically significant ...

Overall survival data showed a 50% reduction in the risk of death with the regimen compared with surgery alone.

Systemic immunotherapy is emerging as a bladder-sparing option for NMIBC, especially for patients unresponsive to BCG therapy ...

The FDA approved the combination of pembrolizumab (Keytruda) and enfortumab vedotin-ejfv (Padcev) for neoadjuvant and ...

A community-based (real-world) study showed that artificial intelligence (AI)-informed analysis of screening mammograms ...

The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...

Findings showed treatment with D-VCd significantly improved MOD-PFS and OS vs treatment with VCd.

Five-year follow-up data from the global, phase 2 JULIET (NCT02445248)trial, which evaluated the chimeric antigen receptor (CAR)T-cell therapy tisagenlecleucel (tisa-cel; Kymriah) in patients with ...

Under Trump policies, cancer registries in 2026 will have to classify sex data strictly as male, female, or unknown, a change ...

A retired nurse who was diagnosed with pancreatic cancer says she feels “incredibly lucky” to be a rare survivor of the disease, which has a five per cent survival rate long term. Suzanne Ford, 67, ...